|
Report No. : |
308168 |
|
Report Date : |
13.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
BASE PHARM CO., LTD. |
|
|
|
|
Registered Office : |
394,
Pyeongchon-daero, Dongan-gu, Anyang-si, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
16.08.2007 |
|
|
|
|
Com. Reg. No.: |
138-81-42401 |
|
|
|
|
Legal Form : |
Company Limited By Shares |
|
|
|
|
Line of Business : |
Wholesale of Other Chemical Materials and Chemical Products |
|
|
|
|
No. of Employees : |
4 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past
four decades has demonstrated incredible growth and global integration to
become a high-tech industrialized economy. In the 1960s, GDP per capita was
comparable with levels in the poorer countries of Africa and Asia. In 2004, South
Korea joined the trillion-dollar club of world economies, and is currently the
world's 12th largest economy. Initially, a system of close government and
business ties, including directed credit and import restrictions, made this
success possible. The government promoted the import of raw materials and
technology at the expense of consumer goods, and encouraged savings and
investment over consumption. The Asian financial crisis of 1997-98 exposed
longstanding weaknesses in South Korea's development model including high
debt/equity ratios and massive short-term foreign borrowing. GDP plunged by
6.9% in 1998, and then recovered by 9% in 1999-2000. South Korea adopted
numerous economic reforms following the crisis, including greater openness to
foreign investment and imports. Growth moderated to about 4% annually between
2003 and 2007. South Korea's export focused economy was hit hard by the 2008
global economic downturn, but quickly rebounded in subsequent years, reaching
6.3% growth in 2010. The US-Korea Free Trade Agreement was ratified by both
governments in 2011 and went into effect in March 2012. Throughout 2012 and
2013 the economy experienced sluggish growth because of market slowdowns in the
United States, China, and the Eurozone. The administration in 2014 is likely to
face the challenge of balancing heavy reliance on exports with developing
domestic-oriented sectors, such as services. The South Korean economy's long
term challenges include a rapidly aging population, inflexible labor market,
dominance of large conglomerates (chaebols), and heavy reliance on exports,
which comprise about half of GDP.
|
Source
: CIA |
|
Company
Name |
BASE PHARM CO., LTD. (Korean Company Name : “베이스팜(주)”) |
|
Registered Address |
394, Pyeongchon-daero,
Dongan-gu, Anyang-si, Gyeonggi-do, Korea |
|
Building |
4FL., BNP Bldg. |
|
Zip Code |
703-042 |
|
Tel |
+82-31-421-1525 |
|
Fax |
+82-31-421-1526 |
|
E-mail |
gloria1346@naver.com;baycom@naver.com |
|
Website |
|
|
Trading Address |
4FL., BNP Bldg.,
394, Pyeongchon-daero, Dongan-gu, Anyang-si, Gyeonggi-do, Korea (Old Address
System : 4FL., BNP Bldg., 1030-8, Bisan 3-dong, Dongan-gu, Anyang-si,
Gyeonggi-do, Korea) |
|
Tel |
+82-31-421-1525 |
|
Fax |
+82-31-421-1526 |
|
Other Address |
|
|
Tel |
|
|
Fax |
|
|
Type |
Export/Import |
|
Industry |
Wholesale of Other Chemical Materials and Chemical Products |
|
Main Business |
Raw Materials for Pharmaceuticals |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
08/16/2007 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Name |
Hur Young-Hoi |
|
Address |
Suite 106-703, 2228, Daehwa-dong,
Ilsanseo-gu, Goyang-si, Gyeonggi-do, Korea |
|
Date of Birth |
07/27/1965 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
220,000,000 |
|
Employees |
4 |
|
Formation |
Co., Ltd by Shares |
|
Bank Details |
Industrial Bank of Korea-Bisan Dong Branch |
|
Corporate Registered No. |
134111-0157532 |
|
Business Registered No. |
138-81-42401 |
|
Permit & Licenses |
Int’l Trade No.: 45328374 |
|
Shareholder Position |
N/A |
|
Company History |
08/16/2007 Incorporated as GLORIA CO., LTD. 01/08/2009 Increased the authorized shares
to 200,000 shares from 40,000 shares 01/09/2009 Increased capital to 220,000,000
KRW from 100,000,000 KRW 02/25/2009 Changed the company name to the
present name 02/25/2009 Moved to 3FL., Daeso Bldg.,
1030-4, Bisan 3-dong, Seo-gu, Daegu, Korea from 1433-36, Gwanyang-dong, Dongan-gu, Anyang-si,
Gyeonggi-do, Korea 05/10/2013 Moved to the present HQ address from 3FL., Daeso Bldg., 1030-4, Bisan 3-dong,
Seo-gu, Daegu, Korea |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Hur Young-Hoi |
Male |
Korean |
03/02/2010 |
|
Director |
Mr. |
Park Yong-Nam |
Male |
Korean |
03/02/2013 |
|
Auditor |
M/S. |
Lee Eun-Joo |
Female |
Korean |
03/02/2013 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
6,061,114,000 |
2,789,856,000 |
646,999,000 |
|
|
2012 |
7,506,039,000 |
2,291,195,000 |
658,804,000 |
|
2011 |
4,337,326,000 |
2,355,569,000 |
191,135,000 |
|
2010 |
4,907,855,000 |
2,069,183,000 |
144,795,000 |
|
2009 |
3,949,595,000 |
1,699,523,000 |
72,680,000 |
|
2008 |
2,059,000,000 |
606,000,000 |
39,000,000 |
|
Authorized Capital(KRW) |
1,000,000,000 |
|
||
|
Paid-Up Capital(KRW) |
220,000,000 |
|
||
|
Total Issues Shares |
44,000 |
|
||
|
Balance Sheet |
||||
|
Unit : Korean Won |
As of 12/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
|
Total Assets |
2,789,856,000 |
2,291,195,000 |
2,355,569,000 |
|
|
Current Assets |
|
|
|
|
|
-Quick Assets |
|
|
|
|
|
-Inventories |
|
|
|
|
|
Fixed Assets |
|
|
|
|
|
-Investment |
|
|
|
|
|
-Tangibles |
|
|
|
|
|
-Intangibles |
|
|
|
|
|
Total Liabilities |
879,553,000 |
986,968,000 |
1,710,147,000 |
|
|
Current Liabilities |
|
|
|
|
|
Fixed Liabilities |
|
|
|
|
|
Capital Stock |
220,000,000 |
220,000,000 |
220,000,000 |
|
|
Capital Surplus |
|
|
|
|
|
Profit Surplus |
|
|
|
|
|
Capital Adjustment |
|
|
|
|
|
Total Equity |
1,910,303,000 |
1,304,227,000 |
645,422,000 |
|
|
Liab. & Shareholder’s Equity |
2,789,856,000 |
2,291,195,000 |
2,355,569,000 |
|
|
Income Statement |
|||
|
Unit : Korean Won |
As of 12/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Sales |
6,061,114,000 |
7,506,039,000 |
4,337,326,000 |
|
Cost of Sold Goods |
|
|
|
|
Gross Profit |
|
|
|
|
Selling & Admin. Expenses |
|
|
|
|
Operating Income |
793,594,000 |
879,082,000 |
261,629,000 |
|
Non-Operating Income |
|
|
|
|
Non-Operating Expenses |
|
|
|
|
Income Before Taxes |
|
|
|
|
Income Taxes Expenses |
|
|
|
|
Net Income |
646,999,000 |
658,804,000 |
191,135,000 |
|
Main Products & Services |
Other Chemical Materials and Chemical Products |
|
Suppliers |
|
|
Customers |
|
|
Competitors |
HIGH TECH PHARM. CO., LTD. 576-1, SEONGBON-RI, DAESO-MYEON,
EUMSEONG-GUN, CHUNGCHEONGBUK-DO, KOREA TEL:+82-43-883-0012 FAX:+82-43-883-0014 HANSEO CHEM CO., LTD. 2-DANJI, POSEUNG NATIONAL INDUSTRIAL
COMPLEX, 1206-14, WONJEONG-RI, POSEUNG-EUP, PYEONGTAEK-SI, GYEONGGI-DO, KOREA TEL:+82-31-682-8655 FAX:+82-31-682-8656 DAEBONG LS CO., LTD. 122B-9L, NAMDONG INDUSTRIAL COMPLEX, 692-8,
GOJAN-DONG, NAMDONG-GU, INCHEON, KOREA TEL:+82-32-817-8800~7 FAX:+82-32-817-8808 |
Not Available.
Not Available.
-----
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.43 |
|
|
1 |
Rs.95.02 |
|
Euro |
1 |
Rs.70.63 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUB |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.